Navigation Links
Unigene Reports Third Quarter 2011 Financial Results
Date:11/9/2011

ived upon the subsequent sale of the SDBG patent portfolio by Kieran Murphy, LLC.

Additional Financial Results & NotesRevenue for the three months ended September 30, 2011 was $3.4 million, compared to $2.9 million for the three months ended September 30, 2010.  Despite the continuing decline in Fortical® royalties, due to increased competition in the nasal calcitonin market, revenue for the three months ended September 30, 2011 was up by $0.5 million to $3.4 million from $2.9 million for the same period in 2010, primarily due to increases in Tarsa and GSK development fees and GSK licensing revenue.  Although Fortical sales and royalties for the nine months ended September 30, 2011 declined by $2.6 million compared with the nine months ended September 30, 2010, total Company revenue only declined by $0.4 million to $8.0 million from $8.4 million for the same period.  The offsetting $2.2 million in non-Fortical revenue originated from Tarsa and GSK development fees, and GSK licensing revenue, as well as revenue from feasibility studies and service fees generated by the newly created Biotechnologies Strategic Business Unit.

Operating loss for the three months ended September 30, 2011 increased approximately $0.5 million, or 28%, to $2.3 million from $1.8 million and, for the nine months ended September 30, 2011, increased approximately $1.4 million, or 18%, to $9.0 million from $7.6 million for the corresponding periods in 2010.

Net loss for the three months ended September 30, 2011 increased approximately $2.9 million, or 66%, to $7.3 million from $4.4 million for the corresponding period in 2010. This was primarily due to non-cash items including our loss recognized on the divestiture of SDBG in the amount of $824,000, our write-down of our investment in Tarsa in the amount of $1.3 million, as well as non-cash interest expense of $2.9 million.

Conference Call and Webcast InstructionsUnigene will host a confer
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011
2. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
3. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
4. GenVec Reports Third Quarter 2011 Financial Results
5. Chindex International, Inc. Reports Financial Results for the Third Quarter and First Nine Months of 2011
6. Allied Healthcare Products Reports First Quarter Loss on Sales Decline
7. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
8. Stereotaxis Reports Third Quarter Financial Results
9. Isis Reports Financial Results and Highlights for Third Quarter 2011
10. Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
11. Anadys Pharmaceuticals Reports Third Quarter 2011 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 20, 2013  AbbVie (NYSE: ABBV ... 3 clinical study called SONAR (Study Of Diabetic ... the investigational compound atrasentan - when added to standard ... patients with stage 2 to 4 chronic kidney ... a large, multinational, double-blind, placebo-controlled clinical study that ...
(Date:5/19/2013)... 20, 2013 Claret Medical, Inc. announced the publication ... Mieghem et al., Histopathology of Embolic Debris ... print in Circulation, May 7 th this research is ... Rotterdam, the Netherlands and the pathology team ... Cardiovascular Pathology Institute, Gaithersburg, Maryland.  This is ...
(Date:5/18/2013)... , May 18, 2013 Although colonoscopy exams ... considered the most sensitive method for detecting colorectal cancers ... preventing cancer cases 3 . EndoChoice ® Inc. ... system significantly improves the accuracy of this procedure and ... EndoChoice will be discussing these clinical trial results and ...
Breaking Medicine Technology:AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3
... , July 19, 2010 Today, Novo Nordisk announced the,landmark recruitment of ... effects of modern insulins in,the management of type 2 diabetes.[1] , ... Spanning 28 countries across 4 continents and involving ... therapy. , , , ...
... Focused Ultrasound Surgery Foundation has announced that eight leading manufacturers are ... Focused Ultrasound, scheduled for October 17 through 20 near ... , , ... edge preclinical, translational and clinical research related to one of today,s ...
Cached Medicine Technology:World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 2World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 3MR-Guided Focused Ultrasound Symposium Announces Sponsors 2MR-Guided Focused Ultrasound Symposium Announces Sponsors 3
(Date:5/20/2013)... California (PRWEB) May 20, 2013 ... done, it's not always to become a celebrity. ... May 7, 2013 ABC News report (“Chris Christie ... made it clear that the surgery was not ... candidate or gain celebrity status as a former ...
(Date:5/20/2013)... May 20, 2013 Fastcare Miami Beach ... infection (UTI) within its first symptoms, as if not treated, ... a more serious infection. Although a urinary tract infection in ... lead to serious kidney infection called pyelonephritis. Women seem to ... come up to the same percentage as women after the ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Daily Gossip, online ... provide its readers with useful tips that can help them ... , According to the website Natural Vitiligo Treatment System ... the numerous positive reviews it has received from the persons ... until now, but Daily Gossip has interviewed some of the ...
(Date:5/20/2013)... New York, NY (PRWEB) May 20, 2013 ... to protecting the rights of victims injured by defective ... South Dakota man who alleges that use of the ... The suit was filed on April 30, 2013, ... of Louisiana (Case No. 6:13-cv-0888), where it is one ...
(Date:5/20/2013)... Angeles, CA (PRWEB) May 20, 2013 According ... Wants Cancer Warnings at Indoor Tanning Salons,” tanning salons ... safety regulations. The Food and Drug Administration wants to see ... implementation of a minimum age floor of eighteen for the ... linked to concerns about melanoma, which has become increasingly common ...
Breaking Medicine News(10 mins):Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 2Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 3Health News:Fastcare Advises on How to Prevent a UTI 2Health News:New Natural Vitiligo Treatment System That Helps People Treat Vitiligo Permanently Revealed by Daily Gossip Magazine 2Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2Health News:Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs 2
... ... 2009CLEVE to get their $54 marrow cheek-swab kit at no cost. , ... (Vocus) June 15, 2009 -- Two-year-old Eve is one of ... but so far her family has been unable to find one. Thanks to the Gift ...
... NATICK, Mass., June 15 Boston Scientific Corporation (NYSE: ... nine studies involving the Company,s Urology/Gynecology products will be ... Urogynecological Association (IUGA). Presentations will feature Boston Scientific,s ... to treat pelvic floor prolapse and stress urinary incontinence ...
... Unique Intelligent Order Routing allows hospital pharmacies to design ... levels , , ROSEMONT, Ill., June 15 ... Omnicell, Inc., (Nasdaq: OMCL ) a leading ... announced the Omnicell WorkflowRx (TM) 6.0 ...
... Early results from the second series of trials have ... a 4.4 log reduction (99.994%) in Methicillin Resistant Staph Aureus ... medical treatment facilities world wide with the spread of MRSA ... CDC reported (JAMA 2007) that MRSA alone is now associated ...
... considering hair replacement surgery is certain to have lots of questions ... it is called "surgery" causes a person to wonder, "Is Hair ... questions that we have regarding hair replacement ," ... explains, "People want to know that they are going to be ...
... Products announced today the first commercial, plant-based diamine oxidase (DAO). ... reports that this new diamine oxidase is orders of magnitude ... enzyme is available as a lyophilized powder. Price will be ... for test assays to detect spoilage by the presence of ...
Cached Medicine News:Health News:Cleveland Residents Lining up to Help Save a Life with Free Donor Kits 2Health News:Boston Scientific's Urology/Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting 2Health News:Boston Scientific's Urology/Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting 3Health News:Boston Scientific's Urology/Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting 4Health News:Boston Scientific's Urology/Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting 5Health News:Boston Scientific's Urology/Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting 6Health News:Omnicell Boosts Pharmacy Efficiency with Enhanced WorkflowRx(TM) Central Pharmacy Automation Software 2Health News:Omnicell Boosts Pharmacy Efficiency with Enhanced WorkflowRx(TM) Central Pharmacy Automation Software 3Health News:Medizone Announces That Its AsepticSure(TM) Development Program is Reaching Objectives on Two Fronts 2Health News:USHairReplacement.com Provides Wealth of Knowledge to Common Hair Replacement Questions 2
Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer...
Conversion Kits For Modular Incubator Chamber...
... The AutoIncubator 96 can incubate and shake ... prepare 96 samples at a time. This ... and enzyme reactions, such as Proteinase K digestion. ... extraction process by preparing your samples with our ...
Inquire...
Medicine Products: